SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT 'ROLES' DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW

Autor: Array Yu. Zakharova, Array R. Gilyarevskiy, Array V. Golshmid, Array A. Orlov, Array I. Sinitsina
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Trandolapril
Ramipril
medicine.medical_specialty
lcsh:Diseases of the circulatory (Cardiovascular) system
Context (language use)
периндоприл
ramipril
RM1-950
Bioinformatics
ингибитор ангиотензин-превращающего фермента
law.invention
Randomized controlled trial
prevention
law
Internal medicine
Perindopril
Medicine
Diseases of the circulatory (Cardiovascular) system
Pharmacology (medical)
Myocardial infarction
trandolapril
Clinical pharmacology
business.industry
трандолаприл
lcsh:RM1-950
рамиприл
medicine.disease
cardiovascular diseases
Endocrinology
профилактика
lcsh:Therapeutics. Pharmacology
angiotensin-converting enzyme inhibitor
lcsh:RC666-701
RC666-701
ACE inhibitor
Therapeutics. Pharmacology
сердечно-сосудистые заболевания
Cardiology and Cardiovascular Medicine
business
perindopril
medicine.drug
Zdroj: Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 7, Iss 1, Pp 70-74 (2016)
ISSN: 2225-3653
1819-6446
Popis: A role of angiotensin-converting enzyme (ACE) inhibitors in cardiovascular diseases treatment and prevention is discussed. Some large randomized clinical trials are analyzed. Physical and chemical properties of drugs and its evidence base are considered among possible factors of ACE inhibitors choice. A problem of ACE inhibitor choice is also discussed in context of secondary prevention of cardiovascular complications in arterial hypertension and after myocardial infarction. It is concluded that the choice of any drug for cardiovascular disease treatment is mainly determined by its evidence base.
Databáze: OpenAIRE
Externí odkaz: